0001564590-22-009118 | 10-K | XBRL Viewer

Print Document View Excel Document

Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 9,144,710	$ 8,068,939
Accounts receivable, net	295,193	23,311
Prepaid expenses	923,746	921,762
Inventory, net	185,534	236,480
Other current assets	11,551	30,300
Total current assets	10,560,734	9,280,792
Operating lease right-of-use asset	12,428	141,705
Other assets		11,551
Total assets	10,573,162	9,434,048
Current Liabilities:
Accounts payable and accrued expenses	874,028	1,273,572
Accrued compensation	519,317	1,016,232
Operating lease liability	12,428	141,705
Paycheck protection program loan		104,168
Milestone payable		5,000,000
Total current liabilities	1,405,773	7,535,677
Long-term Liabilities:
Note payable	5,000,000	5,000,000
Accrued interest payable	612,295	112,994
Total long-term liabilities	5,612,295	5,112,994
Total liabilities	7,018,068	12,648,671
Commitments and contingencies (Note 3)
Stockholders' equity (deficit):
Preferred stock, $0.0001 par value; authorized shares — 5,000,000 at December 31, 2021 and 2020; issued and outstanding shares — 0 at December 31, 2021 and 2020
Common stock, $0.0001 par value; authorized shares — 50,000,000 at December 31, 2021 and 2020; issued and outstanding shares — 32,656,480 and 26,621,954 at December 31, 2021 and 2020, respectively	3,266	2,662
Additional paid-in capital	110,974,841	95,667,776
Accumulated deficit	(107,423,013)	(98,885,061)
Total stockholders' equity (deficit)	3,555,094	(3,214,623)
Total liabilities and stockholders' equity (deficit)	$ 10,573,162	$ 9,434,048

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	32,656,480	26,621,954
Common stock, shares outstanding	32,656,480	26,621,954

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net product sales	$ 1,618,076	$ 23,020
Operating expenses:
Cost of goods sold	328,118	$ 86,712
Cost, Product and Service [Extensible List]		us-gaap:ProductMember
Research and development	590,476	$ 6,554,825
Selling, general and administrative	8,851,129	6,428,832
Total operating expenses	9,769,723	13,070,369
Loss from operations	(8,151,647)	(13,047,349)
Other income (expense):
Forgiveness of paycheck protection loan and accrued interest	105,130
Interest income	8,615	5,672
Interest expense	(500,050)	(112,994)
Total other income (expense)	(386,305)	(107,322)
Net loss	$ (8,537,952)	$ (13,154,671)
Net loss per share of common stock, basic and diluted	$ (0.27)	$ (0.52)
Weighted-average shares used to compute basic and diluted net loss per share	32,185,758	25,492,169

Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2019	$ 4,380,545	$ 2,443	$ 90,108,492	$ (85,730,390)
Beginning Balance, Shares at Dec. 31, 2019		24,431,914
Stock-based compensation expense	1,628,558		1,628,558
Issuance of common stock from employee stock purchase plan	$ 119,416	$ 12	119,404
Issuance of common stock from employee stock purchase plan, shares	118,491	118,491
Issuance of common stock from warrant exercise		$ 38	(38)
Issuance of common stock from warrant exercise, shares	381,625	381,625
Issuance of common stock from stock option exercises	$ 215,816	$ 20	215,796
Issuance of common stock from stock option exercise, shares		199,111
Issuance of common stock from ATM offering, net of costs	3,595,713	$ 149	3,595,564
Issuance of common stock from ATM offering, net of costs, Shares		1,490,813
Net loss	(13,154,671)			(13,154,671)
Ending Balance at Dec. 31, 2020	$ (3,214,623)	$ 2,662	95,667,776	(98,885,061)
Ending Balance, Shares at Dec. 31, 2020	26,621,954	26,621,954
Stock-based compensation expense	$ 1,878,954		1,878,954
Issuance of common stock from employee stock purchase plan, shares	0
Issuance of common stock from warrant exercise, shares	0
Issuance of common stock, net of costs	$ 13,070,154	$ 575	13,069,579
Issuance of common stock, shares net		5,750,000
Issuance of common stock from stock option exercises	45,454	$ 7	45,447
Issuance of common stock from stock option exercise, shares		67,426
Issuance of common stock from ATM offering, net of costs	313,107	$ 22	313,085
Issuance of common stock from ATM offering, net of costs, Shares		217,100
Net loss	(8,537,952)			(8,537,952)
Ending Balance at Dec. 31, 2021	$ 3,555,094	$ 3,266	$ 110,974,841	$ (107,423,013)
Ending Balance, Shares at Dec. 31, 2021	32,656,480	32,656,480

Statements of Stockholders' Equity (Deficit) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement Of Stockholders Equity [Abstract]
Stock Issuance Cost	$ 6,421	$ 73,939

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net loss	$ (8,537,952)	$ (13,154,671)
Adjustments to reconcile net loss to net cash used in operating activities:
Reserve for obsolete inventory	30,000
Forgiveness of paycheck protection loan and accrued interest	(105,130)
Stock-based compensation expense	1,878,954	1,628,558
Change in operating assets and liabilities:
Accounts receivable, net	(271,882)
Prepaid expenses and other assets	157,593	(396,834)
Inventory	20,946	(236,480)
Accounts payable and other current liabilities	(527,859)	243,356
Accrued compensation	(496,915)	173,070
Accrued interest expense	499,301	112,994
Milestone payable	(5,000,000)	5,000,000
Net cash used in operating activities	(12,352,944)	(6,630,007)
Financing activities
Proceeds from issuance of common stock, net	13,070,154
Proceeds from issuance of common stock from ATM, net	313,107	3,595,713
Proceeds from issuance of common stock from employee stock purchase plan		119,416
Proceeds from issuance of common stock from stock options exercises	45,454	215,816
Proceeds from paycheck protection program		104,168
Proceeds from Eversana line of credit		5,000,000
Net cash provided by financing activities	13,428,715	9,035,113
Net increase in cash and cash equivalents	1,075,771	2,405,106
Cash and cash equivalents at beginning of period	8,068,939	5,663,833
Cash and cash equivalents at end of period	9,144,710	8,068,939
Non-cash financing activities
Forgiveness of paycheck protection loan and accrued interest	$ 105,130

Organization and Basis of Presentation

12 Months Ended

Dec. 31, 2021

Organization And Basis Of Presentation [Abstract]

Organization and Basis of Presentation

1. Organization and Basis of Presentation

Evoke Pharma, Inc. (the “Company”) was incorporated under the laws of the state of Delaware in January 2007. The Company is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastroenterological disorders and disease.

Since its inception, the Company has devoted its efforts to developing its sole product, Gimoti (metoclopramide) nasal spray, the first and only nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. On June 19, 2020, the Company received approval from the U.S. Food and Drug Administration (“FDA”) for its 505(b)(2) New Drug Application (“NDA”) for Gimoti. The Company launched U.S. commercial sales of Gimoti in October 2020 through its commercial partner Eversana Life Science Services, LLC (“Eversana”).

The Company’s activities are subject to the significant risks and uncertainties associated with any specialty pharmaceutical company that has launched its first commercial product, including market acceptance of the product and the potential need to obtain additional funding for its operations.

Going Concern

The financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and negative cash flows from operations since inception and expects to continue to incur net losses for the foreseeable future until such time, if ever, that it can generate significant revenues from the sale of Gimoti. The Company ended 2021 with approximately $9.1 million in cash and cash equivalents. The Company anticipates that it will continue to incur losses from operations due to commercialization activities, including manufacturing Gimoti, conducting the post-marketing commitment single-dose pharmacokinetics (“PK”) clinical trial of Gimoti to characterize dose proportionality of a lower dose strength of Gimoti, and for other general and administrative costs to support the Company’s operations. As a result, the Company believes that there is substantial doubt about its ability to continue as a going concern for one year after the date these financial statements are issued. The financial statements do not include any adjustments that may result from the outcome of this uncertainty.

The Company’s net losses may fluctuate significantly from quarter to quarter and year to year. The Company anticipates that it will be required to raise additional funds through debt, equity or other forms of financing, such as potential collaboration arrangements, to fund future operations and continue as a going concern.

There can be no assurance that additional financing will be available when needed or on acceptable terms. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, and/or suspend or curtail commercialization activities. Any of these actions could materially harm the Company’s business, results of operations, financial condition and future prospects. There can be no assurance that the Company will be able to successfully commercialize Gimoti. Because the Company’s business is entirely dependent on the success of Gimoti, if the Company is unable to secure additional financing, successfully commercialize Gimoti or identify and execute on strategic alternatives for Gimoti or the Company, the Company will be required to curtail all of its activities and may be required to liquidate, dissolve or otherwise wind down its operations.

Impact of COVID-19

Despite the COVID-19 pandemic, the Company began its commercial sales of Gimoti with Eversana in October 2020. The Company has experienced various disruptions to its sales activities, but have continued efforts to reach physicians and customers. For example, Eversana’s commercialization efforts at the time the Company launched Gimoti were adversely affected by operational restrictions imposed on its sales force from quarantines, travel restrictions and bans, and other governmental restrictions related to COVID-19. As a result of these restrictions, Eversana’s sales force was restricted from conducting in-person interactions with certain physicians and customers and was restricted to conducting Gimoti educational and promotional activities virtually in certain circumstances, which impacted Eversana’s ability to more actively market Gimoti. In recent months, certain physician offices have begun to allow more frequent in-person interactions, which has helped to increase the educational and promotional activities of the sales force. The Company anticipates that it and Eversana will continue to be impacted by the COVID-19 pandemic to some extent.

The COVID-19 pandemic has not significantly disrupted the operations of the Company’s third-party suppliers and manufacturers or delayed the Company’s manufacturing timelines of Gimoti, but may negatively impact the Company’s ability to successfully commercialize Gimoti and generate product sales in the future. Further, the COVID-19 pandemic and related mitigation measures have also had an adverse impact on global economic conditions which could have an adverse effect on the Company’s future business and financial condition, including impairing its ability to raise capital when needed.

In March 2020, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was enacted in response to the COVID-19 pandemic. In April 2020, the Company applied for and was approved for a Small Business Administration (“SBA”) loan under the Paycheck Protection Program, established by the CARES Act. On May 1, 2020, the Company received the loan proceeds of approximately $104,000. In January 2021, the Company received notice that its loan and accrued interest were forgiven by the SBA.

Notice of Delisting

On December 29, 2021, the Company received a letter from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market.

In accordance with Nasdaq listing rules, the Company was provided an initial period of 180 calendar days, or until June 27, 2022, to regain compliance. The letter states that Nasdaq will provide written notification that the Company has achieved compliance with its rules if at any time before June 27, 2022, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. The Nasdaq letter had no immediate effect on the listing or trading of the Company’s common stock and the common stock continued to trade on The Nasdaq Capital Market.

The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq’s minimum bid price rule by June 27, 2022.

If the Company does not regain compliance with Nasdaq listing rules by June 27, 2022, the Company may be eligible for an additional 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq would notify the Company that its securities would be subject to delisting. In the event of such a notification, the Company may appeal Nasdaq’s determination to delist its securities, but there can be no assurance Nasdaq would grant the Company’s request for continued listing.

The Company has not regained compliance with Nasdaq listing rules as of the date these financial statements were issued.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Use of Estimates

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Segment Reporting

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment operating in the United States.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents include cash in readily available checking and savings accounts.

Fair Value of Financial Instruments

The carrying amounts of all financial instruments, including accounts receivable and accounts payable and accrued expenses, are considered to be representative of their respective fair values because of the short-term nature of those instruments. The carrying value of other short-term and long-term borrowings approximates fair value because of the relative short maturity of these instruments and the interest rates the Company could currently obtain.

Concentrations of Risk

Financial instruments that potentially subject the Company to significant credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits.

The Company has established guidelines designed to maintain safety and liquidity, has not experienced any losses in such accounts and believes the exposure to significant risk to the cash balance is minimal.

The Company relies on contract research organizations (“CROs”) and consultants to assist with ongoing regulatory activities. If the CROs and consultants are unable to continue their support, this could adversely affect the Company’s operations.

In addition, the Company relies on third-party manufacturers for the production of Gimoti. If the third-party manufacturers are unable to continue manufacturing Gimoti, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet any development needs or commercial supply demand for Gimoti, and the development and/or commercialization of Gimoti could be materially and adversely affected.

The Company also relies on a dedicated third-party sales team to sell Gimoti. If such third-party organization is unable to continue serving as a dedicated sales team, the commercialization of Gimoti could be materially and adversely affected.

Accounts Receivable

Accounts receivable are recorded net of allowance for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on existing contractual obligations and historical payment patterns. The allowance for doubtful accounts was zero at December 31, 2021 and December 31, 2020, and no bad debt expense was recorded for the years ended December 31, 2021 and December 31, 2020.

Inventory

The Company does not own or operate manufacturing facilities for the production of Gimoti, nor does it plan to develop its own manufacturing operations in the foreseeable future. The Company depends on third-party contract manufacturers for all of its required raw materials, drug substance and finished product for its commercial manufacturing. The Company has agreements with Cosma S.p.A. to supply metoclopramide for the manufacture of Gimoti, and with Thermo Fisher Scientific, Inc., through its subsidiary Patheon UK Limited, for the manufacturing of Gimoti. The Company currently utilizes third-party consultants, which it engages on an as-needed, hourly basis, to manage the manufacturing contractors.

Prior to FDA approval of Gimoti in June 2020, the cost of materials and expenses associated with the manufacturing of Gimoti were recorded as research and development expense. Subsequent to FDA approval, the Company began manufacturing Gimoti for commercialization and began capitalizing inventory at that time. The Company’s inventory, consisted of approximately $150,000 of raw materials at December 31, 2021 and 2020, and approximately $35,000 and $86,000 of finished goods at December 31, 2021 and December 31, 2020, respectively. Inventories are stated at the lower of cost (first-in first-out basis) or net realizable value. Inventory at December 31, 2021 was written down by $30,000 due to establishing a reserve for obsoletion. The new cost basis and its value is not to be subsequently increased based upon changes in underlying facts and circumstances. The Company’s raw materials inventory is held at its third-party suppliers and its finished goods inventory is held at its manufacturer and at Eversana. The Company records such inventory as consigned inventory.

Revenue Recognition

The Company’s ability to generate revenue and become profitable depends on its ability to successfully commercialize Gimoti, which was launched in the United States through prescription in October 2020 through the Company’s commercial partner Eversana. If the Company or Eversana fail to successfully launch Gimoti and grow and maintain sales, the Company may never generate significant revenues and its results of operations and financial position will be adversely affected.

In accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods in an amount that reflects the consideration the Company expects to receive in exchange for the goods provided. Customer control is determined upon the customer’s physical receipt of the product. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with the customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) it satisfies a performance obligation. At contract inception, the Company assesses the goods promised within each contract and determines those that are performance obligations and assesses whether each promised good is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the customer obtains control of the product.

Product sales are recorded at the transaction price, which may include variable considerations for co-payment assistance to commercially insured patients meeting certain eligibility requirements, as well as to uninsured patients. Co-payment assistance is recorded as an offset to gross revenue at the time revenue from the product sale is recognized based on expected and actual program participation. Co-pay liabilities are estimated using prescribing data available from customers. Actual amounts of consideration ultimately received may materially differ from the Company’s estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in

the period such variances become known. Liabilities for co-pay assistance of approximately $44,000 are classified as accounts payable and accrued expenses in the balance sheets.

During the year ended December 31, 2021, approximately $718,000 of Gimoti was sold to a third party for research purposes.

Stock-Based Compensation

Stock-based compensation expense for stock option grants and employee stock purchases under the Company’s Employee Stock Purchase Plan (the “ESPP”) is recorded at the estimated fair value of the award as of the grant date and is recognized as expense on a straight-line basis over the employee’s requisite service period, except awards with a performance condition. Awards with a performance condition commence vesting when the satisfaction of the performance condition is probable. The estimation of stock option and ESPP fair value requires management to make estimates and judgments about, among other things, employee exercise behavior, forfeiture rates and volatility of the Company’s common stock. The judgments directly affect the amount of compensation expense that will be recognized.

The Company grants stock options to purchase common stock to employees and members of the board of directors with exercise prices equal to the Company’s closing market price on the date the stock options are granted. The risk-free interest rate assumption was based on the yield of an applicable rate for U.S. Treasury instruments with maturities similar to those of the expected term of the award being valued. The weighted average expected term of options and employee stock purchases was calculated using the simplified method as prescribed by accounting guidance for stock-based compensation. This decision was based on the lack of relevant historical data due to the Company’s limited historical experience. In addition, due to the Company’s limited historical data, the estimated volatility was calculated based upon the Company’s historical volatility, supplemented, as necessary, with historical volatility of comparable companies in the biotechnology industry whose share prices are publicly available for a sufficient period of time. The assumed dividend yield was based on the Company never paying cash dividends and having no expectation of paying cash dividends in the foreseeable future. The Company accounts for forfeitures as the forfeitures occur.

Research and Development Expenses

Research and development costs are expensed as incurred and primarily include compensation and related benefits, stock-based compensation expense, costs paid to third-party contractors for product development activities and drug product materials, and technology acquisition milestones. The Company has expensed costs relating to the purchase and production of pre-approval inventories as research and development expense in the period incurred prior to FDA approval received on June 19, 2020. The Company will expense the clinical, regulatory and manufacturing costs related to the post-marketing commitment to conduct a single dose PK clinical trial of Gimoti to characterize dose proportionality of a lower dose strength of Gimoti, as well as other costs that may occur for any additional clinical trials the Company may pursue to expand the indication of Gimoti.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Under ASC 740, deferred tax assets and liabilities reflect the future tax consequences of the differences between the financial reporting and tax basis of assets and liabilities using current enacted tax rates. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized.

The Company’s policy related to accounting for uncertainty in income taxes prescribes a recognition threshold and measurement attributed criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities.

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of warrants to purchase common stock, options to purchase common stock under the Company’s equity incentive plans and potential shares to be purchased under the ESPP.

The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive for the years ended December 31, 2021 and 2020:

	Year Ended December 31,
	2021	2020
Warrants to purchase common stock	1,679,673		1,841,879
Common stock options	5,013,459		4,077,259
Employee stock purchase plan	—		12,242
Total excluded securities	6,693,132		5,931,380

Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board, (“FASB”) issued ASU 2016-13, Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available-for-sale debt securities. This update is effective for annual periods beginning after December 15, 2022, and interim periods within those periods, and early adoption is permitted. We expect to adopt the standard on its effective date in the first quarter of 2023. We believe the adoption will modify the way we analyze financial instruments, but currently do not expect the adoption to have a material financial impact on our financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options, or Subtopic 470-20 and Derivatives and Hedging—Contracts in Entity’s Own Equity, or Subtopic 815-40: Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share, or EPS, calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. We believe the adoption will modify the way we analyze financial instruments, but currently do not expect the adoption to have a material financial impact on our financial statements.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

3. Commitments and Contingencies

Leases

In December 2016, the Company entered into an operating lease for office space in Solana Beach, California. The lease commenced on January 1, 2017, was extended in September 2018, December 2019, December 2020 and February 2022, and has an expiration date of October 31, 2022, subject to the landlord’s option to cancel upon 30 days written notice, but not sooner than July 31, 2022. According to ASU No. 2016-02, the Company recognized an operating lease ROU asset and liability based on the present value of the future minimum lease payments over the lease term at the commencement date, using the Company’s assumed incremental borrowing rate, and then amortizes the ROU assets over the lease term. The Company applies a discount rate to the minimum lease payments within the lease agreement to determine the value of right-of-use assets and lease liabilities. Unless the rate implicit in the lease is determinable, ASU No. 2016-02 requires the use of the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term for a similar amount to the lease payments in a similar economic environment. The Company noted that the implicit rate in the lease was not determinable and calculated its incremental borrowing rate primarily based on the Company’s assumed borrowing rate of 10% for the years ended December 31, 2021 and 2020. Upon adoption of ASU No. 2016-02 on January 1, 2019, the Company recorded an operating lease ROU asset and liability of approximately $136,000 based on the present value of the remaining minimum lease payments. As of December 31, 2021 and 2020, the Company had an operating lease ROU asset and liability of approximately $12,000 and $142,000, respectively, based on the present value of the remaining minimum lease payments. During the years ended December 31, 2021 and 2020, changes in operating lease ROU asset and payments of the lease liability were included in prepaid expenses and other assets and accounts payable and accrued expense, respectively, on the statement of cash flows.

Rent expense for the years ended December 31, 2021 and 2020 was approximately $136,000 and $151,000, respectively. The Company also pays pass through costs and utility costs, which are expensed as incurred.

As of December 31, 2021, the Company has future minimum lease payments under its existing facility lease of approximately $12,000 payable in 2022. The lease was amended in February 2022 resulting in approximately $112,000 future minimum lease payments under the amended facility lease in 2022.

Legal Proceedings

On February 25, 2022, the Company received a letter dated February 24, 2022, notifying us that Teva submitted to the FDA an abbreviated new drug application, or ANDA, for a generic version of Gimoti (metoclopramide hydrochloride) nasal spray eq. 15 mg base/spray that contains Paragraph IV certifications with respect to two of our patents covering Gimoti, U.S. Patent Nos. 8,334,281, expiration date May 16, 2030; and 11,02,0361, expiration date December 22, 2029. These patents are listed in FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book, for Gimoti. The certifications allege these patents are invalid or will not be infringed by the manufacture, use or sale of Teva’s metoclopramide hydrochloride nasal spray eq. 15 mg base/spray. The Company anticipates initiating litigation against Teva over the validity and infringement of the patents covering Gimoti.

Technology Acquisition Agreement

12 Months Ended

Dec. 31, 2021

Technology Acquisition Agreement [Abstract]

Technology Acquisition Agreement

4. Technology Acquisition Agreement

In June 2007, the Company acquired all worldwide rights, data, patents and other related assets associated with Gimoti from Questcor Pharmaceuticals, Inc. (“Questcor”) pursuant to an asset purchase agreement. The Company paid Questcor $650,000 in the form of an upfront payment and $500,000 in May 2014 as a milestone payment based upon the initiation of the first patient dosing in the Company’s Phase 3 clinical trial for Gimoti. In August 2014, Mallinckrodt, plc (“Mallinckrodt”) acquired Questcor. As a result of that acquisition, Questcor transferred its rights included in the asset purchase agreement with the Company to Mallinckrodt. In addition to the payments previously made to Questcor, the Company may also be required to make additional milestone payments totaling up to $52 million. In March 2018, the Company and Mallinckrodt amended the asset purchase agreement to defer development and approval milestone payments, such that, rather than paying two milestone payments based on FDA acceptance for review of the NDA and final product marketing approval, the Company would be required to make a single $5 million payment on the one-year anniversary after the Company receives FDA approval to market Gimoti. At the time of the Gimoti NDA approval by FDA, the Company recorded the $5 million payable owed to Mallinckrodt, along with a $5 million research and development expense. The $5 million milestone payment was paid in July 2021.

The remaining $47 million in milestone payments depend on Gimoti’s commercial success. The Company is required to pay Mallinckrodt a low single digit royalty percentage on net sales of Gimoti. As of December 31, 2021, the Company has paid Mallinckrodt approximately $51,000 for royalties on net sales of Gimoti. The Company’s obligation to pay such royalties will terminate upon the expiration of the last patent right covering Gimoti, which is expected to occur in 2030, subject to possible extension should any additional, later expiring, licensed patents be granted.

Preferred Stock, Common Stock and Stockholders' Equity

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Preferred Stock, Common Stock and Stockholders' Equity

5. Preferred Stock, Common Stock and Stockholders’ Equity

Preferred Stock

Under the Company’s amended and restated certificate of incorporation, the Company is authorized to issue 5,000,000 shares of preferred stock with a $0.0001 par value. No shares of preferred stock were outstanding as of December 31, 2021 or 2020.

Common Stock

As of December 31, 2021, there were 32,656,480 shares of common stock outstanding. Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company. To date, no dividends have been declared.

Sale of Common Stock in Public Offering

In January 2021, the Company completed the sale of 5,750,000 shares of its common stock in an underwritten public offering led by Laidlaw & Company (UK) Ltd. The price to the public in this offering was $2.50 per share resulting in gross proceeds to the Company of approximately $14.4 million. After deducting underwriting discounts and commissions and offering expenses paid by the Company, the net proceeds to the Company raised from this offering were approximately $13.1 million.

At the Market Equity Offering Program

In November 2017, the Company filed a shelf registration with the SEC on Form S-3. The shelf registration statement included a prospectus for the at-the-market offering to sell up to an aggregate of $16.0 million of shares of the Company’s common stock through B. Riley FBR, Inc. (“FBR”) as a sales agent (the “FBR Sales Agreement”). During the year ended December 31, 2020, the Company sold 1,490,813 shares of common stock at a weighted-average price per share of $2.46 pursuant to the FBR Sales Agreement and received proceeds of approximately $3.6 million, net of commissions and fees. Effective January 6, 2021, the Company terminated the FBR Sales Agreement. As a result, there were no shares sold under the FBR Sales Agreement during 2021.

In December 2020, the Company filed a new shelf registration statement with the SEC on Form S-3, or the replacement shelf registration statement. The replacement shelf registration statement replaced the registration statement on Form S-3 the Company originally filed with the SEC in November 2017, which registration statement expired in December 2020. The replacement shelf registration was declared effective by the SEC on January 6, 2021. In December 2020, the Company also entered into a new At Market Issuance Sales Agreement (the “ATM Sales Agreement”), with FBR and H.C. Wainwright & Co. (together with FBR, the “Sales Agents”), pursuant to which the Company may sell from time to time, at its option, up to an aggregate of $30 million worth of shares of the Company’s common stock through the Sales Agents. The ATM Sales Agreement provides, among other things, that sales under the ATM Sales Agreement will be made pursuant to the registration statement, including the base prospectus filed as part of such registration statement. During the year ended December 31, 2021, the Company sold 217,100 shares of common stock at a weighted-average price per share of $1.47 pursuant to the ATM Sales Agreement and received proceeds of approximately $313,000, net of commissions and fees.

From January 1, 2022 through February 28, 2022, the Company sold 261,421 shares of common stock at a weighted-average price per share of $0.67 pursuant to the ATM Sales Agreement and received proceeds of approximately $172,000, net of commissions and fees.

Future sales under the ATM Sales Agreement will depend on a variety of factors including, but not limited to, market conditions, the trading price of the Company’s common stock and the Company’s capital needs. There can be no assurance that the Sales Agents will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices that the Company deems appropriate.

In addition, the Company will not be able to make future sales of common stock pursuant to the ATM Sales Agreement unless certain conditions are met, which include the accuracy of representations and warranties made to the Sales Agents under the ATM Sales Agreement. Furthermore, each of the Sales Agents is permitted to terminate the ATM Sales Agreement with respect to itself in its sole discretion upon ten days’ notice, or at any time in certain circumstances, including the occurrence of an event that would be reasonably likely to have a material adverse effect on the Company’s assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders’ equity or results of operations. The Company has no obligation to sell the shares available for sale pursuant to the ATM Sales Agreement.

Warrants

The Company has issued warrants to purchase common stock to banks that have previously loaned funds to the Company, as well as to representatives of the underwriters of the Company’s public offerings and certain of their affiliates.

For the year ended December 31, 2020, certain holders of warrants exercised their warrants to purchase 871,682 shares of the Company’s common stock by a “cashless” exercise and received 381,625 shares of the Company’s common stock. The warrants had a weighted average exercise price of $2.77 per share. The shares were issued, and the warrants were originally sold, in reliance upon the registration exemption set forth in Section 4(a)(2) of the Securities Act of 1933. There were no warrants exercised in 2021, and warrants to purchase 162,206 shares of common stock expired during 2021.

At December 31, 2021 and 2020, there were warrants outstanding to purchase 1,679,673 and 1,841,879 shares of the Company’s common stock with a weighted average exercise price of $2.90 and $2.98, respectively. At December 31, 2021, the weighted average remaining contractual term of the outstanding warrants is 0.08 years. From January 1, 2022 through February 28, 2022, warrants to purchase 1,667,673 shares of common stock have expired.

Equity Incentive Award Plans

In August 2013, the Company adopted the 2013 Equity Incentive Award Plan (the “2013 Plan”). Under the 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company. Since its adoption, the Company’s stockholders have amended and restated the 2013 Plan. As of April 2018, the Company’s stockholders increased the number of shares of common stock authorized for issuance under the 2013 Plan to an aggregate of 6,286,425 shares, and extended the term of the 2013 Plan to February 2028. In addition, the number of shares available for issuance is annually increased on the first day of each fiscal year by that number of shares equal to the least of (a) four percent of the outstanding shares of common stock on the last day of the immediately preceding calendar year, and (b) such other amount determined by the Company’s board of directors. Notwithstanding the foregoing, the number of shares of common stock that may be issued or transferred pursuant to incentive stock options under the Restated Plan may not exceed an aggregate of 8,000,000 shares.

As a result of the annual increases since the 2013 Plan originated, and the increase of stock options reserved under the restatements of the 2013 Plan approved by the Company’s stockholders through April 2018, the Company has increased the number shares reserved for issuance under the 2013 Plan by 6,115,681 shares. As of December 31, 2021, 1,463,685 options remain available for future grant under the 2013 Plan. On January 1, 2022, the Company further increased the number of shares reserved for issuance under the 2013 Plan by 1,306,259 shares, making 2,769,944 options available for future grant under the 2013 Plan.

Options granted under the 2013 Plan have ten-year terms from the date of grant and generally vest over a one to four year period. The Company granted options to purchase 1,682,000 and 1,172,000 shares of common stock in 2021 and 2020,

respectively. The exercise price of all options granted during the years ended December 31, 2021 and 2020 was equal to the market value per share of the Company’s common stock on the date of grant.

A summary of the Company’s stock option activity under the 2013 Plan is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding at December 31, 2020		4,077,259		$	1.70		8.09	$	5,134,768
Granted		1,682,000		$	2.42		9.13	—
Exercised		(67,426	)	$	0.67		7.39	$	43,715
Expired/Forfeited/Exchanged		(678,374	)	$	2.85		6.54	$	3,923
Outstanding at December 31, 2021		5,013,459		$	1.80		7.85	—

Vested and expected to vest at December 31, 2021		5,024,473		$	1.80		7.85	—

Exercisable at December 31, 2021		2,580,048		$	1.83		7.27	—

The intrinsic values above represent the aggregate value of the total pre-tax intrinsic value based upon a common stock price of $0.55 and $2.58 at December 31, 2021 and 2020, respectively, and the contractual exercise price.

The weighted average grant date fair value per share of employee stock options granted during the years ended December 31, 2021 and 2020, was $1.93 and $1.23, respectively.

Employee Stock Purchase Plan

In June 2013, the Company’s board of directors adopted the ESPP, and the Company’s stockholders approved the ESPP on August 29, 2013. The ESPP became effective on the day prior to the effectiveness of the IPO. The ESPP permits participants to purchase the Company’s common stock at 85% of the fair market value through payroll deductions of up to 20% of their eligible compensation. A total of 30,000 shares of common stock were initially reserved for issuance under the ESPP. In addition, the number of shares of common stock available for issuance under the ESPP has been annually increased on the first day of each fiscal year during the term of the ESPP by an amount equal to the lesser of: (i) 30,000 shares; (ii) one percent of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine.

In May 2017, the Company’s stockholders approved an amendment and restatement of the Company’s ESPP to increase the number of shares of common stock reserved under the ESPP by 100,000 shares (to an aggregate of 1,250,000 shares), to increase the annual evergreen provision from 30,000 shares to 100,000 shares, and to extend the term of the ESPP into 2027. The Company increased the number shares reserved for issuance under the ESPP by 620,000 shares since the inception of the ESPP. As of December 31, 2021, 344,574 shares remain available for future issuance under the ESPP. On January 1, 2022, the Company further increased the number of shares reserved for future issuance under the ESPP by 100,000 shares, making 444,574 shares available for future issuance under the ESPP after that increase.

Payroll withholdings from the Company’s employees of approximately $119,000 resulted in the issuance of 118,491 shares of common stock through its ESPP during the year ended December 31, 2020. No shares of common stock were issued through the ESPP during 2021.

Stock-Based Compensation

Stock-based compensation expense includes charges related to employee stock purchases under the ESPP and stock option grants. The Company measures stock-based compensation expense based on the grant date fair value of any awards granted to its employees. Such expense is recognized over the period of time that employees provide service and earn rights to the awards.

The estimated fair value of each stock option award granted was determined on the date of grant using the Black Scholes option-pricing valuation model with the following assumptions for option grants during the years ended December 31, 2021 and 2020:

	Year Ended December 31,
	2021	2020
Risk free interest rate	0.57% - 1.08%	0.39% - 0.96%
Expected option term	5.5 - 6.0 years	5.5 - 6.0 years
Expected volatility of common stock	103.45% - 107.53%	99.73% - 103.99%
Expected dividend yield	0.0%	0.0%

The estimated fair value of the shares to be acquired under the ESPP was determined on the initiation date of each six-month purchase period using the Black-Scholes option-pricing valuation model with the following assumptions for ESPP shares to be purchased during the years ended December 31, 2021 and 2020 as follows:

	Year Ended December 31,
	2021	2020
Risk free interest rate	0.13%	0.13% - 1.11%
Expected term	0.5 years	0.5 years
Expected volatility of common stock	111.98%	69.72% - 111.98%
Expected dividend yield	0.0%	0.0%

The Company recognized stock-based compensation expense to employees and directors in its research and development and its general and administrative functions during the years ended December 31, 2021 and 2020 as follows:

	Year Ended December 31,
	2021	2020
Research and development	$ 101,754	$	316,892
Selling, general and administrative	1,777,200		1,311,666
Total stock-based compensation expense	$ 1,878,954	$	1,628,558

As of December 31, 2021, there was approximately $2.9 million of unrecognized compensation costs related to outstanding employee and board of director options, which are expected to be recognized over a weighted-average period of 1.32 years.

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consists of the following at December 31, 2021 and 2020:

	December 31,
	2021		2020
Stock options issued and outstanding		5,013,459		4,077,259
Authorized for future option grants		1,463,685		1,402,433
Warrants to purchase common stock		1,679,673		1,841,879
Authorized for employee stock purchase plan		344,574		244,574
Total common stock reserved for future issuance		8,501,391		7,566,145

Employee Benefit Plan

12 Months Ended

Dec. 31, 2021

Compensation And Retirement Disclosure [Abstract]

Employee Benefit Plan

6. Employee Benefit Plan

The Company has established a defined contribution 401(k) plan (the “Plan”) for all employees who are at least 21 years of age. Employees are eligible to participate in the Plan beginning on the date of employment. Under the terms of the Plan, employees may make voluntary contributions as a percentage of compensation. The Company’s contributions to the Plan are discretionary, and no contributions have been made by the Company to date. For the years ended December 31, 2021 and 2020, the Company adopted Safe Harbor 401(k) provisions. No contributions were required to be made to the accounts of employees for the years ended December 31, 2021 and 2020 in order to maintain the Plan’s compliance with Internal Revenue Service regulations.

Commercial Services and Loan Agreements with Eversana

12 Months Ended

Dec. 31, 2021

Commercial Services And Loan Agreements [Abstract]

Commercial Services and Loan Agreements with Eversana

7. Commercial Services and Loan Agreements with Eversana

On January 21, 2020, the Company entered into a commercial services agreement (the “Eversana Agreement”) with Eversana for the commercialization of Gimoti. Pursuant to the Eversana Agreement, Eversana commercializes and distributes Gimoti in the United States. Eversana also manages the marketing of Gimoti to targeted health care providers, as well as the sales and distribution of Gimoti in the United States.

Under the terms of the Eversana Agreement, the Company maintains ownership of the Gimoti NDA, as well as legal, regulatory, and manufacturing responsibilities for Gimoti. Eversana will utilize its internal sales organization, along with other commercial functions, for market access, marketing, distribution and other related patient support services. The Company will record sales for Gimoti and retain more than 80% of net product profits once the parties’ costs are reimbursed. For the years ended December 31, 2021 and 2020, approximately $1.3 million and $16,000 of Eversana profit sharing costs were included as sales, general and administrative costs, respectively. As of December 31, 2021, unreimbursed commercialization costs to Eversana were approximately $27.0 million. Such costs will generally be payable only as net product profits are recognized. Eversana will receive reimbursement of its commercialization costs pursuant to an agreed upon budget and a percentage of product profits in the mid-to-high teens. Net product profits are the net sales (as defined in the Eversana Agreement) of Gimoti, less (i) reimbursed commercialization costs, (ii) manufacturing and administrative costs set at a fixed percentage of net sales, and (iii) third party royalties. During the term of the Eversana Agreement, Eversana agreed to not market, promote, or sell a competing product in the United States. On February 1, 2022, the Eversana Agreement was amended (the “Amended Eversana Agreement”) to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms. This amendment also increased the percentage of net product profit retained by the Company and increased the proportion of costs that are reimbursed to Eversana to the extent Eversana has accumulated unreimbursed costs

Upon expiration or termination of the agreement, the Company will retain all profits from product sales and assume all corresponding commercialization responsibilities. Within 30 days after each of the first three annual anniversaries of commercial launch, either party may terminate the agreement if net sales of Gimoti do not meet certain annual thresholds. Either party may terminate the agreement: for the material breach of the other party, subject to a 60-day cure period; in the event an insolvency, petition of the other party is pending for more than 60 days; upon 30 days written notice to the other party if Gimoti is subject to a safety recall; the other party is in breach of certain regulatory compliance representations under the agreement; if the Company discontinues the development or production of Gimoti; if the net profit is negative for any two consecutive calendar quarters beginning with the first full calendar quarter 24 months following commercial launch; if the cumulative net product profits fail to reach certain thresholds in the first three years following launch; or if there is a change in applicable laws that makes operation of the services as contemplated under the agreement illegal or commercially impractical. Either party may also terminate the Amended Eversana Agreement upon a change of control of the Company’s ownership. In the event that the Company initiates such termination, the Company shall pay to Eversana a one-time payment equal to all of Eversana’s unreimbursed cost plus a portion of Eversana’s commercialization costs incurred in the 12 months prior to termination. Such payment amount would be reduced by the amount of previously reimbursed commercialization costs and profit split paid for the related prior twelve-month period and any revenue which occurred prior to the termination yet to be collected. If Eversana terminates the agreement due to an uncured material breach by the Company, or if the Company terminates the Eversana Agreement in certain circumstances, the Company has agreed to reimburse Eversana for its unreimbursed commercialization costs for the prior twelve-month period and certain other costs. In addition, Eversana may terminate the Eversana Agreement if the Company withdraws Gimoti from the market for more than 90 days.

In connection with the Eversana Agreement, the Company and Eversana have entered into the Eversana Credit Facility, pursuant to which Eversana has agreed to provide a revolving Credit Facility of up to $5 million to the Company upon FDA approval of the Gimoti NDA under certain customary conditions. The Eversana Credit Facility terminates on June 25, 2025, unless terminated earlier pursuant to its terms. The Eversana Credit Facility is secured by all of the Company’s personal property other than the Company’s intellectual property. Under the terms of the Eversana Credit Facility, the Company cannot grant an interest in the Company’s intellectual property to any other person. Each loan under the Eversana Credit Facility will bear interest at an annual rate equal to 10.0%, with such interest due at the end of the loan term. In June 2020 the

Company borrowed $2 million and in December 2020 it borrowed the remaining $3 million under the Eversana Credit Facility.

The Company may prepay any amounts borrowed under the Eversana Credit Facility at any time without penalty or premium. The maturity date of all amounts, including interest, borrowed under the Eversana Credit Facility will be 90 days after the expiration or earlier termination of the Eversana Agreement. The Eversana Credit Facility also includes events of default, the occurrence and continuation of which provide Eversana with the right to exercise remedies against the Company and the collateral securing the loans under the Eversana Credit Facility, including the Company’s cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the Eversana Credit Facility, an uncured material breach of the representations, warranties and other obligations under the Eversana Credit Facility, the occurrence of insolvency events and the occurrence of a change in control.

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

8. Income Taxes

The Company accounts for uncertain tax positions in accordance with ASC Topic 740, Income Taxes. The application of income tax law and regulations is inherently complex. Interpretations and guidance surrounding income tax laws and regulations change over time. As such, changes in the Company’s subjective assumptions and judgments can materially affect amounts recognized in its financial statements.

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest and penalties on the balance sheet at December 31, 2021. The Company has an uncertain tax position (“UTP”) of approximately $2.0 million related to California net operating losses at December 31, 2021. The Company is subject to taxation in the United States and state jurisdictions, and the Company’s tax years beginning 2007 to date are subject to examination by taxing authorities.

Deferred income taxes result from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in years in which those temporary differences are expected to be recovered or settled. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through income tax expense.

A reconciliation of the federal statutory income tax rate and the effective income tax rate is as follows for the years ended December 31, 2021 and 2020:

	December 31,
	2021			2020
	(%)			(%)
Federal statutory rate	21				21
Change in valuation allowance		5			(3	)
Research and development credits	—				(1	)
Removal of net operating losses and other credits		(25	)		(11	)
Impact of state tax rate change	—				(2	)
Stock compensation and other permanent items		(1	)		(4	)
Effective income tax rate	—			—

Pursuant to Internal Revenue Code of 1986 (“IRC”) Sections 382 and 383, annual use of the Company’s net operating loss and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards. Until this analysis has been completed, the Company has excluded the deferred tax assets for net operating losses of approximately $22.5 million and a research and development credit of approximately $3.6 million generated through December 31, 2021 from its deferred tax asset. When this analysis is finalized, the Company plans to update its unrecognized tax benefits accordingly. The Company does not expect this analysis to be completed within the next twelve months and, as a result, the Company does not expect that the unrecognized tax benefits will change within twelve months of this reporting date. Due to the existence of the valuation allowance, future changes in the Company’s unrecognized tax benefits will not impact the Company’s effective tax rate.

Significant components of the Company’s deferred tax assets at December 31, 2021 and 2020 are as follows:

	December 31,
	2021			2020
Deferred tax assets:
Acquired technology	$	543,000		$	1,089,000
Stock compensation expense		1,413,000			1,139,000
Lease liability		3,000			59,000
Accruals and other		110,000			214,000
Total deferred tax assets		2,069,000			2,501,000
Deferred tax liabilities:
Right of use asset		(3,000	)		(59,000	)
Total deferred tax liabilities		(3,000	)		(59,000	)
Less valuation allowance		(2,066,000	)		(2,442,000	)
Net deferred tax assets (liabilities)	$	—		$	—

At December 31, 2021, the Company corrected the balance of deferred tax assets at December 31, 2020 relating to stock compensation expense as well as the valuation allowance related to those assets by an equal and offsetting amount. The deferred tax assets and valuation allowance as of December 31, 2020 has been increased in the table above by $444,000 due to the impact of the misclassification of stock option type for tax purposes. The Company carries a full valuation allowance against these deferred tax assets, therefore, the adjustments had no effect on the balance sheets, statements of operations and cash flows for the periods presented.

At December 31, 2021, the Company has federal and California net operating loss carryforwards of approximately $91.3 million and $47.8 million, respectively. The federal and California net operating loss carryforwards begin to expire in 2027 and 2028, respectively, unless previously utilized. The portion of federal net operating losses created after 2017 of approximately $29.4 million do not expire and will carry forward indefinitely. At December 31, 2021, the Company also has federal and California research tax credit carryforwards of approximately $2.4 million and $1.5 million, respectively. The federal research credit carryforwards will begin expiring in 2027 unless previously utilized. The California research credit will carry forward indefinitely. Furthermore, under U.S. tax legislation enacted in December 2017, although the treatment of tax losses generated before December 31, 2017 has generally not changed, tax losses generated in calendar year 2018 and beyond do not expire, but may only offset 80% of the Company’s taxable income. This change may require us to pay federal income taxes in future years despite generating a loss for federal income tax purposes in prior years.

The CARES Act, among other things, permits net operating loss carryforwards generated in taxable years beginning after December 31, 2017, to offset 100% of taxable income for taxable years beginning before January 1, 2021, and 80% of taxable income in taxable years beginning after December 31, 2020. The CARES Act did not have a material impact on the Company’s financial results for the year ended December 31, 2021.

California Assembly Bill 85 (“AB 85”), which intends to close a gap in the budget created by the COVID-19 pandemic, was signed into law on June 29, 2020. AB 85 disallows California net operating losses for any taxable year beginning on or after January 1, 2020 and before January 1, 2023 for any corporation with a net business or modified adjusted gross income of more than $1 million for the taxable year. This bill also limits any business credit to offset a maximum of $5 million of California tax, including the California research credit. The Company has a taxable loss for the year ended December 31, 2021, and therefore is not affected by the limitation.

There were no changes to unrecognized tax benefits in 2021 and 2020. As such, the balance of unrecognized tax benefits (excluding interest and penalties) was approximately $2.0 million at December 31, 2021 and 2020. The Company will recognize interest and penalties related to unrecognized tax benefits as income tax expense when incurred. To date, since no benefit has been taken related to the UTP, there has been no interest and penalties recognized.

Due to the full valuation allowance that the Company has on the deferred tax assets, there are no unrecognized tax benefits that would impact the effective tax rate, if recognized.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Subsequent Events

12 Months Ended

Dec. 31, 2021

Subsequent Events [Abstract]

Subsequent Events

9. Subsequent Events

For the purposes of the financial statements as of December 31, 2021 and the year then ended, the Company has evaluated subsequent events through the date the audited annual financial statements were issued. The Company has concluded that no subsequent event has occurred that required disclosure in the financial statements other than what has been disclosed.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Use of Estimates

Segment Reporting

Cash and Cash Equivalents

Fair Value of Financial Instruments

Concentrations of Risk

Accounts Receivable

Inventory

Revenue Recognition

the period such variances become known. Liabilities for co-pay assistance of approximately $44,000 are classified as accounts payable and accrued expenses in the balance sheets.

During the year ended December 31, 2021, approximately $718,000 of Gimoti was sold to a third party for research purposes.

Stock-Based Compensation

Research and Development Expenses

Income Taxes

Net Loss Per Share

	Year Ended December 31,
	2021	2020
Warrants to purchase common stock	1,679,673		1,841,879
Common stock options	5,013,459		4,077,259
Employee stock purchase plan	—		12,242
Total excluded securities	6,693,132		5,931,380

Recent Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share

	Year Ended December 31,
	2021	2020
Warrants to purchase common stock	1,679,673		1,841,879
Common stock options	5,013,459		4,077,259
Employee stock purchase plan	—		12,242
Total excluded securities	6,693,132		5,931,380

Preferred Stock, Common Stock and Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Summary of Stock Option Activity

A summary of the Company’s stock option activity under the 2013 Plan is as follows:

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding at December 31, 2020		4,077,259		$	1.70		8.09	$	5,134,768
Granted		1,682,000		$	2.42		9.13	—
Exercised		(67,426	)	$	0.67		7.39	$	43,715
Expired/Forfeited/Exchanged		(678,374	)	$	2.85		6.54	$	3,923
Outstanding at December 31, 2021		5,013,459		$	1.80		7.85	—

Vested and expected to vest at December 31, 2021		5,024,473		$	1.80		7.85	—

Exercisable at December 31, 2021		2,580,048		$	1.83		7.27	—

Summary of Estimated Fair Value of Stock Option Award

	Year Ended December 31,
	2021	2020
Risk free interest rate	0.57% - 1.08%	0.39% - 0.96%
Expected option term	5.5 - 6.0 years	5.5 - 6.0 years
Expected volatility of common stock	103.45% - 107.53%	99.73% - 103.99%
Expected dividend yield	0.0%	0.0%

Summary of Estimated Fair Value of Shares to be Acquired under Employee Stock Purchase Plan

	Year Ended December 31,
	2021	2020
Risk free interest rate	0.13%	0.13% - 1.11%
Expected term	0.5 years	0.5 years
Expected volatility of common stock	111.98%	69.72% - 111.98%
Expected dividend yield	0.0%	0.0%

Summary of Recognized Stock-Based Compensation Expense

	Year Ended December 31,
	2021	2020
Research and development	$ 101,754	$	316,892
Selling, general and administrative	1,777,200		1,311,666
Total stock-based compensation expense	$ 1,878,954	$	1,628,558

Summary of Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consists of the following at December 31, 2021 and 2020:

	December 31,
	2021		2020
Stock options issued and outstanding		5,013,459		4,077,259
Authorized for future option grants		1,463,685		1,402,433
Warrants to purchase common stock		1,679,673		1,841,879
Authorized for employee stock purchase plan		344,574		244,574
Total common stock reserved for future issuance		8,501,391		7,566,145

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Reconciliation of Federal Statutory Income Tax Rate and Effective Income Tax Rate

A reconciliation of the federal statutory income tax rate and the effective income tax rate is as follows for the years ended December 31, 2021 and 2020:

	December 31,
	2021			2020
	(%)			(%)
Federal statutory rate	21				21
Change in valuation allowance		5			(3	)
Research and development credits	—				(1	)
Removal of net operating losses and other credits		(25	)		(11	)
Impact of state tax rate change	—				(2	)
Stock compensation and other permanent items		(1	)		(4	)
Effective income tax rate	—			—

Summary of Significant Components of Deferred Tax Assets

Significant components of the Company’s deferred tax assets at December 31, 2021 and 2020 are as follows:

	December 31,
	2021			2020
Deferred tax assets:
Acquired technology	$	543,000		$	1,089,000
Stock compensation expense		1,413,000			1,139,000
Lease liability		3,000			59,000
Accruals and other		110,000			214,000
Total deferred tax assets		2,069,000			2,501,000
Deferred tax liabilities:
Right of use asset		(3,000	)		(59,000	)
Total deferred tax liabilities		(3,000	)		(59,000	)
Less valuation allowance		(2,066,000	)		(2,442,000	)
Net deferred tax assets (liabilities)	$	—		$	—

Organization and Basis of Presentation - Additional Information (Detail) - USD ($)		12 Months Ended
	May 01, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization And Basis Of Presentation [Line Items]
Month and year of incorporation		2007-01
Cash and cash equivalents		$ 9,144,710	$ 8,068,939	$ 5,663,833
COVID-19 [Member] \| Paycheck Protection Program [Member]
Organization And Basis Of Presentation [Line Items]
Proceeds from loan	$ 104,000

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2021 USD ($) Segment	Dec. 31, 2020 USD ($)
Significant Accounting Policies [Line Items]
Number of operating segment \| Segment	1
Allowance for doubtful accounts receivable	$ 0	$ 0
Bad debt expense	0	0
Inventory raw materials	150,000	150,000
Inventory finished goods	35,000	$ 86,000
Inventory reserve for obsoletion	30,000
Gimoti [Member]
Significant Accounting Policies [Line Items]
Purchase by third party for research purposes	718,000
Accounts Payable and Accrued Expenses [Member]
Significant Accounting Policies [Line Items]
Liabilities for co-pay assistance	$ 44,000

Summary of Significant Accounting Policies - Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of diluted net loss per share	6,693,132	5,931,380
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of diluted net loss per share	1,679,673	1,841,879
Common stock options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of diluted net loss per share	5,013,459	4,077,259
Employee stock purchase plan [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of diluted net loss per share		12,242

Commitments and Contingencies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Feb. 28, 2022	Jan. 01, 2019
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Lease commencement date	Jan. 01, 2017
Lease expiry date	Oct. 31, 2022
Operating lease incremental borrowing rate	10.00%	10.00%
Operating lease ROU asset	$ 12,000	$ 142,000		$ 136,000
Operating lease ROU liability	12,000	142,000		$ 136,000
Rent expense	136,000	$ 151,000
Future minimum facility lease payments due in 2022	$ 12,000
Subsequent Event
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Future minimum facility lease payments due in 2022			$ 112,000

Technology Acquisition Agreement - Additional Information (Detail)	1 Months Ended			12 Months Ended
	Jul. 31, 2021 USD ($)	May 31, 2014 USD ($)	Jun. 30, 2007 USD ($)	Dec. 31, 2021 USD ($) Milestone	Dec. 31, 2020 USD ($)	Jun. 30, 2021 USD ($)
Technology Acquisition Agreement [Line Items]
Payment expensed as in-process research and development			$ 650,000
Milestone payment				$ (5,000,000)	$ 5,000,000
Mallinckrodt Plc [Member]
Technology Acquisition Agreement [Line Items]
Milestone payments contingent amount				$ 5,000,000
Number of milestone payments \| Milestone				1
Mallinckrodt Plc [Member] \| Gimoti [Member]
Technology Acquisition Agreement [Line Items]
Milestone payment	$ 5,000,000
Amount payable to Mallinckro dt						$ 5,000,000
Research and development expense payable					$ 5,000,000
Mallinckrodt Plc [Member] \| Rights and Patents Acquired from Questcor Pharmaceuticals Inc [Member] \| Maximum [Member]
Technology Acquisition Agreement [Line Items]
Milestone payments contingent amount				$ 52,000,000
Development Target One [Member] \| Rights and Patents Acquired from Questcor Pharmaceuticals Inc [Member]
Technology Acquisition Agreement [Line Items]
Milestone payment		$ 500,000
Development targets description				upon the initiation of the first patient dosing in the Company’s Phase 3 clinical trial for Gimoti.
Development Target Four [Member] \| Mallinckrodt Plc [Member] \| Patented Technology [Member]
Technology Acquisition Agreement [Line Items]
Development targets description				depend on Gimoti’s commercial success. The Company is required to pay Mallinckrodt a low single digit royalty percentage on net sales of Gimoti.
Milestone payments contingent amount				$ 47,000,000
Expected expiration of patent right				2030
Royalties on net sales				$ 51,000

Preferred Stock, Common Stock and Stockholders' Equity - Preferred Stock - Additional Information (Detail) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares outstanding	0	0

Preferred Stock, Common Stock and Stockholders' Equity - Common Stock - Additional Information (Detail) - USD ($)	1 Months Ended	2 Months Ended	12 Months Ended
	Jan. 31, 2021	Feb. 28, 2022	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2017
Sale Of Common Stock [Line Items]
Common stock, shares outstanding			32,656,480	26,621,954
Shareholders voting power description			Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.
Dividends declared on common stock			$ 0
Common stock, shares issued			32,656,480	26,621,954
Proceeds from issuance of common stock, net			$ 13,070,154
Public Offering [Member]
Sale Of Common Stock [Line Items]
Common stock, shares issued	5,750,000
Shares issued, price per share	$ 2.50
Proceeds from issuance of common stock, net	$ 14,400,000
Proceeds from issuance of common stock net of underwriting discounts and commissions and offering expenses	$ 13,100,000
FBR Sales Agreement [Member]
Sale Of Common Stock [Line Items]
Common stock, shares issued			0	1,490,813
Proceeds from issuance of common stock, net				$ 3,600,000
Common stock , weighted average price per share				$ 2.46
FBR Sales Agreement [Member] \| Maximum [Member]
Sale Of Common Stock [Line Items]
Common stock, value of shares issuable					$ 16,000,000.0
ATM Sales Agreement [Member]
Sale Of Common Stock [Line Items]
Common stock, shares issued			217,100
Proceeds from issuance of common stock, net			$ 313,000
Common stock , weighted average price per share			$ 1.47
ATM Sales Agreement [Member] \| Subsequent Event
Sale Of Common Stock [Line Items]
Common stock, shares issued		261,421
Proceeds from issuance of common stock, net		$ 172,000
Common stock , weighted average price per share		$ 0.67
ATM Sales Agreement [Member] \| Maximum [Member]
Sale Of Common Stock [Line Items]
Available for the issuance of common stock				$ 30,000,000

Preferred Stock, Common Stock and Stockholders' Equity - Warrants - Additional Information (Detail) - $ / shares	2 Months Ended	12 Months Ended
	Feb. 28, 2022	Dec. 31, 2021	Dec. 31, 2020
Sale Of Stock [Line Items]
Warrants converted to purchase of common stock			871,682
Warrants to purchase shares of common stock expired		162,206
Issuance of common stock from warrant exercise		0	381,625
Weighted average exercise price of warrants exercised			$ 2.77
Warrants outstanding to purchase common stock		1,679,673	1,841,879
Weighted average exercise price of warrants outstanding		$ 2.90	$ 2.98
Weighted average remaining contractual term of outstanding warrants		29 days
Subsequent Event
Sale Of Stock [Line Items]
Warrants to purchase shares of common stock expired	1,667,673

Preferred Stock, Common Stock and Stockholders' Equity - Equity Incentive Award Plans - Additional Information (Detail) - $ / shares			12 Months Ended
	Jan. 01, 2022	Apr. 26, 2018	Dec. 31, 2021	Dec. 31, 2020
Sale Of Stock [Line Items]
Aggregate number of shares of common stock reserved under the plan		6,286,425	8,501,391	7,566,145
Award plan expiration month and year		2028-02
Options available for future grant			1,463,685	1,402,433
Options granted, weighted average term			10 years
Number of stock options granted			1,682,000	1,172,000
Intrinsic value, common stock price			$ 0.55	$ 2.58
Weighted Average Grant Date Fair Value Per Share, Granted			$ 1.93	$ 1.23
Minimum [Member]
Sale Of Stock [Line Items]
Options granted, vesting period			1 year
Maximum [Member]
Sale Of Stock [Line Items]
Options granted, vesting period			4 years
Amended and Restated Equity Incentive Plan 2013 [Member]
Sale Of Stock [Line Items]
Aggregate number of shares of common stock reserved under the plan		8,000,000
Shares available for issuance, description			In addition, the number of shares available for issuance is annually increased on the first day of each fiscal year by that number of shares equal to the least of (a) four percent of the outstanding shares of common stock on the last day of the immediately preceding calendar year, and (b) such other amount determined by the Company’s board of directors. Notwithstanding the foregoing, the number of shares of common stock that may be issued or transferred pursuant to incentive stock options under the Restated Plan may not exceed an aggregate of 8,000,000 shares.
Amended and Restated Equity Incentive Plan 2013 [Member] \| Annual Increase in Shares [Member]
Sale Of Stock [Line Items]
Reserve percentage for issuance of shares		4.00%
2013 Equity Incentive Award Plan [Member]
Sale Of Stock [Line Items]
Increase in the number of shares of common stock reserved under the plan			6,115,681
Options available for future grant			1,463,685
Number of stock options granted			1,682,000
2013 Equity Incentive Award Plan [Member] \| Subsequent Event
Sale Of Stock [Line Items]
Increase in the number of shares of common stock reserved under the plan	1,306,259
Options available for future grant	2,769,944

Preferred Stock, Common Stock and Stockholders' Equity - Summary of Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding beginning balance	4,077,259
Options, Granted	1,682,000	1,172,000
Options, Outstanding ending balance	5,013,459	4,077,259
2013 Equity Incentive Award Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options, Outstanding beginning balance	4,077,259
Options, Granted	1,682,000
Options, Exercised	(67,426)
Options, Expired/Forfeited/Exchanged	(678,374)
Options, Outstanding ending balance	5,013,459	4,077,259
Options, Vested and expected to vest at December 31, 2021	5,024,473
Options, Exercisable at December 31, 2021	2,580,048
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price, Outstanding beginning balance	$ 1.70
Weighted Average Exercise Price, Granted	2.42
Weighted Average Exercise Price, Exercised	0.67
Weighted Average Exercise Price, Expired/Forfeited/Exchanged	2.85
Weighted Average Exercise Price, Outstanding ending balance	1.80	$ 1.70
Weighted Average Exercise Price, Vested and expected to vest at December 31, 2021	1.80
Weighted Average Exercise Price, Exercisable at December 31, 2021	$ 1.83
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]
Weighted Average Remaining Contractual Term (Years), Outstanding	7 years 10 months 6 days	8 years 1 month 2 days
Weighted Average Remaining Contractual Term (Years), Granted	9 years 1 month 17 days
Weighted Average Remaining Contractual Term (Years), Exercised	7 years 4 months 20 days
Weighted Average Remaining Contractual Term (Years), Expired/Forfeited/Exchanged	6 years 6 months 14 days
Weighted Average Remaining Contractual Term (Years), Vested and expected to vest at December 31, 2021	7 years 10 months 6 days
Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2021	7 years 3 months 7 days
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value [Abstract]
Aggregate Intrinsic Value, Outstanding beginning balance	$ 5,134,768
Aggregate Intrinsic Value, Exercised	43,715
Aggregate Intrinsic Value, Expired/Forfeited/Exchanged	$ 3,923
Aggregate Intrinsic Value, Outstanding ending balance		$ 5,134,768

Preferred Stock, Common Stock and Stockholders' Equity - Employee Stock Purchase Plan and Stock-Based Compensation - Additional Information (Detail) - USD ($)		1 Months Ended		12 Months Ended
	Jan. 01, 2022	May 31, 2017	Jun. 30, 2013	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Apr. 26, 2018	Apr. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation costs				$ 2,900,000
Weighted average period				1 year 3 months 25 days
Aggregate number of shares of common stock reserved under the plan				8,501,391	7,566,145		6,286,425
Shares of common stock available for future issuance under ESPP				344,574	244,574
Stock issued during period, shares, period increase						620,000
Issuance of common stock under employee stock purchase plan				0	118,491
Payroll withholdings from employees					$ 119,000
Amended and Restated ESPP [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate number of shares of common stock reserved under the plan		1,250,000
Number of shares increased annually to common stock shares reserved for issuance		100,000						30,000
Award plan expiration year		2027
Employee stock purchase plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price of common stock as percentage of fair market value			85.00%
Percentage of deduction of eligible compensation			20.00%
Aggregate number of shares of common stock reserved under the plan			30,000
Shares available for issuance, description				In addition, the number of shares of common stock available for issuance under the ESPP has been annually increased on the first day of each fiscal year during the term of the ESPP by an amount equal to the lesser of: (i) 30,000 shares; (ii) one percent of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine.
Reserve percentage for issuance of shares			1.00%
ESPP approval date			Aug. 29, 2013
Subsequent Event \| Employee stock purchase plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Aggregate number of shares of common stock reserved under the plan	444,574
Stock issued during period, shares, period increase	100,000

Preferred Stock, Common Stock and Stockholders' Equity - Summary of Estimated Fair Value of Stock Option Award (Detail) - Common stock options [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free interest rate	0.57%	0.39%
Expected option term	5 years 6 months	5 years 6 months
Expected volatility of common stock	103.45%	99.73%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free interest rate	1.08%	0.96%
Expected option term	6 years	6 years
Expected volatility of common stock	107.53%	103.99%

Preferred Stock, Common Stock and Stockholders' Equity - Summary of Estimated Fair Value of Shares to be Acquired under Employee Stock Purchase Plan (Detail) - Employee stock purchase plan [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free interest rate	0.13%
Expected term	6 months	6 months
Expected volatility of common stock	111.98%
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free interest rate		0.13%
Expected volatility of common stock		69.72%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free interest rate		1.11%
Expected volatility of common stock		111.98%

Preferred Stock, Common Stock and Stockholders' Equity - Summary of Recognized Stock-Based Compensation Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,878,954	$ 1,628,558
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	101,754	316,892
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,777,200	$ 1,311,666

Preferred Stock, Common Stock and Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail) - shares	Dec. 31, 2021	Dec. 31, 2020	Apr. 26, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock options issued and outstanding	5,013,459	4,077,259
Authorized for future option grants	1,463,685	1,402,433
Warrants to purchase common stock	1,679,673	1,841,879
Authorized for employee stock purchase plan	344,574	244,574
Total common stock reserved for future issuance	8,501,391	7,566,145	6,286,425

Employee Benefit Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Postemployment Benefits [Abstract]
Eligible age for employees for participating in the plan	21 years
Company's contributions to employee benefit plan	$ 0	$ 0

Commercial Services and Loan Agreements with Eversana - Additional Information (Detail) - USD ($)			12 Months Ended
	Feb. 01, 2022	Jan. 21, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020
Commercial Services And Loan Agreements [Line Items]
Selling, general and administrative			$ 8,851,129	$ 6,428,832
Eversana Agreement [Member]
Commercial Services And Loan Agreements [Line Items]
Unreimbursed commercialization cost			$ 27,000,000.0
Agreement term			On February 1, 2022, the Eversana Agreement was amended (the “Amended Eversana Agreement”) to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms.
Selling, general and administrative			$ 1,300,000	16,000
Eversana Agreement [Member] \| Revolving Credit Facility [Member]
Commercial Services And Loan Agreements [Line Items]
Line of credit		$ 5,000,000
Line of credit facility, Interest rate		10.00%
Borrowings				$ 3,000,000	$ 2,000,000
Eversana Agreement [Member] \| Gimoti [Member] \| Minimum [Member]
Commercial Services And Loan Agreements [Line Items]
Percentage of Product Profits		80.00%
Eversana Agreement [Member] \| Subsequent Event
Commercial Services And Loan Agreements [Line Items]
Agreement expiration date	Dec. 31, 2026

Income Taxes - Additional Information (Detail) - USD ($)		12 Months Ended
	Jun. 29, 2020	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Accrual on interest and penalties related to income taxes		$ 0
Uncertain tax position		2,000,000.0	$ 2,000,000.0
Removal of net operating losses from deferred tax assets		$ 22,500,000
Cumulative change in ownership for limitation of use of net operating loss and research and development credit carryforwards		50.00%
Period of cumulative change of ownership		3 years
Removal of research and development credit from deferred tax assets		$ 3,600,000
Deferred tax asset, Valuation allowance increase (decrease)			444,000
Percentage of taxable income offset by tax losses		80.00%
Changes to unrecognized tax benefits		$ 0	$ 0
Unrecognized tax benefits that would affect company's effective tax rate, if recognized		$ 0
Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Tax years subject to examination by taxing authorities		2007
Percentage of annual usage limitation on net operating loss carryforward		100.00%
Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Percentage of annual usage limitation on net operating loss carryforward		80.00%
California [Member]
Operating Loss Carryforwards [Line Items]
Uncertain tax position		$ 2,000,000.0
Net operating loss carry forwards		$ 47,800,000
Expiry date of carry forwards		Dec. 31, 2028
California [Member] \| Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carry forwards		$ 1,500,000
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry forwards		$ 91,300,000
Expiry date of carry forwards		Dec. 31, 2027
Net operating loss carryforwards, not subject to expiration		$ 29,400,000
Federal [Member] \| Research Tax Credit Carryforward [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carry forwards		$ 2,400,000
CALIFORNIA [Member]
Operating Loss Carryforwards [Line Items]
Maximum amount of tax offset per year	$ 5,000,000
Required minimum taxable income	$ 1,000,000

Income Taxes - Reconciliation of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal statutory rate	21.00%	21.00%
Change in valuation allowance	5.00%	(3.00%)
Research and development credits		(1.00%)
Removal of net operating losses and other credits	(25.00%)	(11.00%)
Impact of state tax rate change		(2.00%)
Stock compensation and other permanent items	(1.00%)	(4.00%)

Income Taxes - Summary of Significant Components of Deferred Tax Assets (Detail) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Acquired technology	$ 543,000	$ 1,089,000
Stock compensation expense	1,413,000	1,139,000
Lease liability	3,000	59,000
Accruals and other	110,000	214,000
Total deferred tax assets	2,069,000	2,501,000
Deferred tax liabilities:
Right of use asset	(3,000)	(59,000)
Total deferred tax liabilities	(3,000)	(59,000)
Less valuation allowance	$ (2,066,000)	$ (2,442,000)